Market
Will Stanford's synthetic GPCRs be used in a clinical trial by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries such as ClinicalTrials.gov
Story
Stanford Unveils Synthetic GPCRs for Programmable Cell Sensing in Nature Biotechnology
Dec 5, 2024, 12:34 PM
A groundbreaking study from Stanford University introduces synthetic G protein-coupled receptors (GPCRs) designed to sense diverse antigens and trigger a range of intracellular responses. These programmable antigen-gated GPCRs (PAGERs), developed by Alice Y. Ting's lab at Stanford, represent a new frontier in programmable sensing and control of cell behavior, potentially revolutionizing immunotherapy and targeted drug delivery. The technology aims to detect both soluble and cell-attached antigens, converting recognition into intracellular responses like transgene expression and real-time monitoring of cellular processes. This innovation, highlighted in Nature Biotechnology, could lead to the development of programmable expression logic gates, offering new tools for prevention-focused healthcare and enhancing the precision of treatments for various diseases.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Bacterial infections • 25%
Viral infections • 25%
Cancer treatment • 25%
Autoimmune diseases • 25%
Yes • 50%
No • 50%
Roche • 25%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Mixed results • 25%
Negative results • 25%
Positive results with MRD-negative CR • 25%
Trial discontinued • 25%